Dr. Reddy's semaglutide restart hangs on three validation batches after a scale up impurity

Dr. Reddy's semaglutide now has approvals in ten countries, but its pens still wait on one step inside its own ingredient plant. The Indian generic maker's results deck of 23 October says it is on track to fix the problem that stopped supply in July, when a scaled up batch of drug substance failed testing. The restart depends on three validation batches passing. This is a process story: a larger batch size changed how the molecule behaved, and the fix runs through validation, not new equipment.

How a scale up stopped supply

On 9 July Dr. Reddy's told Indian and US exchanges that certain batches of semaglutide were out of specification because of an issue tied to the active pharmaceutical ingredient. In the 9 July disclosure, the company said commercial supplies would be delayed while it investigated, and that patient safety and its existing regulatory filings were not affected. Chief executive Erez Israeli explained the cause on a call the same day. To meet demand, the company had scaled up its synthetic ingredient process at its own facility to raise output. The ingredient itself met its specification, he said, but one impurity went out of limits when the finished drug was tested, which meant the ingredient was degrading during formulation.

Israeli said the impurity came from the process and the reaction used to make the ingredient. Asked whether equipment would have to change, he said that to the best of his understanding it would not, and that the company needed to adjust process parameters to control the impurity. Because the failure showed up during validation of the new scale, those batches never reached patients, he said, and there was no recall linked to them. He separately mentioned a recall of one batch in India that he said was unrelated. Smaller scale production would continue in limited amounts. Validation of the new scale, he added, needs no new approval from any regulator, because neither the specification nor the filing changes.

What validation has to prove

The fix runs through a fixed sequence. Israeli told analysts the company would tweak the process, make three new validation batches, ship that ingredient to OneSource Specialty Pharma, its long term partner that fills the pens, and then test the finished product. Some of those tests take up to three weeks because of sterility checks. Only after that can commercial quantities of ingredient move to OneSource. In July he put the earliest end of validation at around the end of September, with supply to the market resuming in late October or early November. He also said there was "a risk of a further delay." The plan he described had OneSource filling 6 to 7 million pens between November and March.

Every failed validation batch pushes the whole chain back, because the pen filler cannot start until the ingredient behind it has passed.

Every failed validation batch pushes the whole chain back, because the pen filler cannot start until the ingredient behind it has passed. Dr. Reddy's has a backup ingredient supplier, but Israeli said in the 9 July call that it is not the same supplier and would need a pre approval supplement, putting it about a year away. Tablets were not affected, he said, because the oral product uses a different ingredient source. Demand was not the limit: he said the company could sell more pens than planned if it had them. That makes the ingredient step the single point that sets how many Dr. Reddy's semaglutide pens reach the market this winter.

The cost and the countries waiting

The company booked a provision of 2,397 million rupees for inventory and related costs tied to the ingredient in the quarter to June. Its results release said this cut gross, EBITDA and pre tax margins by about 3 percentage points. In the quarter to September, the Q2 deck shows EBITDA margin back at 20.6 percent on revenue of 8,671 crore rupees, down 1.5 percent from a year earlier, which the company linked mainly to lower sales of lenalidomide. The deck says generic semaglutide is approved in ten countries across Latin America, Africa and the Middle East, plus Canada and India, with eight of those approvals in emerging markets. It gives no restart date of its own and simply calls the fix on track.

Canada is the main destination. Dr. Reddy's launched its injection there in May after Health Canada approval in April, as the first generic semaglutide in a G7 country by its own account. According to a report on the 23 October call by ctol.digital, Israeli said relaunch is expected in November, directly and through partners, subject to validation, with most of the first quantities going to Canada and smaller amounts to Latin America and Africa. That timing comes from a call summary rather than a filed document. In India, the same report cites Reuters on new pen brands made by Hetero Labs, which Dr. Reddy's says were planned before July, while our story on Chinese makers lining up copies shows rivals gathering elsewhere.

What the Dr. Reddy's semaglutide case shows about peptide process

The Dr. Reddy's semaglutide case shows how fragile scale up can be for a long synthetic peptide. The company makes the chain by chemistry rather than growing it in yeast, a route difference set out in our explainer on yeast or resin routes. A larger batch can change heat transfer, mixing and reaction times, and any of those can shift the impurity profile. Here the ingredient passed its own release test, and the problem appeared only later, once it was formulated into the drug product. That gap is why validation runs end to end, from ingredient to filled pen, rather than stopping at the ingredient plant. The cost of a missed step is months of lost supply, not just a scrapped batch.

The episode also shows the value of a second qualified source, and how long one takes. Israeli's estimate of about a year for the backup supplier reflects the regulatory work needed before any new ingredient source can feed an approved product. Purification is part of the same picture, since impurities that form during scale up must be removed or prevented, which is why tools such as the new DuPont silica media target crude cleanup and final polishing. No company has linked those products to this case. The open points are whether the three batches pass, whether the November restart holds, and how quickly OneSource can fill the pens.

Conclusion

Dr. Reddy's semaglutide supply depends on three validation batches at its own ingredient plant, after a scale up in July produced an impurity that appeared only in the finished drug. The company holds approvals in ten countries, booked a 2,397 million rupee provision, and says the fix is on track. A November relaunch, mostly for Canada, is expected only if validation passes, and the backup supplier is about a year away.